Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Leading Edge Materials' Investor Update and Significant Activities (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Bolt Biotherapeutics Inc BOLT

Healthcare Biotechnology
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I... see more

Bullboard (NDAQ:BOLT)

View:
Post by Tulsa123on Jan 08, 2025 11:08am

Is bolt a good buy?

What the opinion out there?
30
User Avatar Image
(11)
•••
  • TradeVanguard27X
Post by TradeVanguard27on Nov 27, 2024 3:54pm

BOLT Completes NI 43-101 Report for Switchback Property—Reso

Bolt Metals has wrapped up its NI 43-101 technical report for the Switchback Copper-Silver Property. This milestone could pave the way for resource estimates and future development. Investors, watch ...more  
55
User Avatar Image
(10)
•••
  • MikeTesterX
Post by MikeTesteron Aug 03, 2024 4:17pm

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT): Pivoting to a Focu

https://beyondspx.com/2024/08/02/bolt-biotherapeutics-inc-nasdaqbolt-pivoting-to-a-focused-pipeline-and-streamlined-operations-to-maximize-shareholder-value/
71
Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities